RxSight, Inc. (RXST)
Automate Your Wheel Strategy on RXST
With Tiblio's Option Bot, you can configure your own wheel strategy including RXST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RXST
- Rev/Share 3.9103
- Book/Share 6.895
- PB 2.2755
- Debt/Equity 0.0431
- CurrentRatio 12.6826
- ROIC -0.1268
- MktCap 637594530.0
- FreeCF/Share -0.5084
- PFCF -30.9557
- PE -23.9441
- Debt/Assets 0.0385
- DivYield 0
- ROE -0.0954
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RXST | Wells Fargo | Equal Weight | Overweight | -- | $25 | May 19, 2025 |
| Initiation | RXST | Piper Sandler | -- | Neutral | -- | $18 | April 15, 2025 |
| Downgrade | RXST | UBS | Buy | Neutral | -- | $16 | April 9, 2025 |
| Downgrade | RXST | JP Morgan | Overweight | Underweight | $40 | $17 | April 4, 2025 |
| Downgrade | RXST | BofA Securities | Buy | Underperform | $36 | $22 | April 3, 2025 |
| Downgrade | RXST | Stifel | Buy | Hold | $65 | $40 | Dec. 20, 2024 |
| Downgrade | RXST | Wells Fargo | Overweight | Equal Weight | $56 | $42 | Dec. 11, 2024 |
| Initiation | RXST | UBS | -- | Buy | -- | $52 | Dec. 6, 2024 |
| Reiterated | RXST | Needham | -- | Buy | $54 | $66 | Aug. 20, 2024 |
News
RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President & Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Steve Lichtman - Oppenheimer David Saxon - Needham & Company Adam Maeder - Piper Sandler Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Craig Bijou - Bank of America Tom Stephan - Stifel Operator Thank you for standing by. At this time, I would like to welcome everyone to …
Read More
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.12 per share a year ago.
Read More
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance
Published: April 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time.
Read More
RxSight, Inc. (RXST) Misses Q4 Earnings Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
RxSight, Inc. (RXST) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.26 per share a year ago.
Read More
About RxSight, Inc. (RXST)
- IPO Date 2021-07-30
- Website https://www.rxsight.com
- Industry Medical - Devices
- CEO Dr. Ronald M. Kurtz M.D.
- Employees 498